FDA discusses topics in complex generic topical products. Includes responses to audience in a question-and-answer panel. Presenters and presentations include:
“No Difference” Standard vs. Q1|Q2 Sameness for Topical Drug Products
Megan Kelchen, PhD; DTP I|ORS|OGD|CDER
Use of Q3 Characterization Tests for Topical Semisolid Drug Products
Sam Raney, PhD; IO|ORS|OGD|CDER
Recent Research Related to Q3 Characterization of Topical Products Containing Porous Microparticles
Ahmed Zidan, PhD; DPQR|OTR|OPQ|CDER
Challenges and Considerations with Model-based Virtual Bioequivalence Assessments for Generic Dermatological Products
Eleftheria Tsakalozou, PhD; DQMM|ORS|OGD|CDER
Khondoker Alam, PhD; DQMM|ORS|OGD|CDER
Q&A Panel (Including all above presenters):
Markham Luke, MD, PhD; DTP I|ORS|OGD|CDER
For slides and additional information: [ Ссылка ]
--------------------
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming Training - [ Ссылка ]
SBIA Listserv - [ Ссылка ]
SBIA 2021 Playlist - [ Ссылка ]
SBIA LinkedIn - [ Ссылка ]
SBIA Training Resources - [ Ссылка ]
Twitter - [ Ссылка ]
Email - CDERSBIA@fda.hhs.gov
Phone - (301) 796-6707 I (866) 405-5367
